Testosterone Receptor Mechanism: How T Works Inside Your Cells

What the Androgen Receptor Is and Where It Lives

The androgen receptor (AR) is a ligand-activated transcription factor encoded by a gene on chromosome Xq11-12. When testosterone or dihydrotestosterone (DHT) binds it, the receptor changes shape, moves into the cell nucleus, and switches specific genes on or off. Without that conformational shift, circulating testosterone is essentially inert.

AR protein sits in the cytoplasm, held in an inactive state by heat-shock proteins HSP90 and HSP70 [1]. Once testosterone diffuses across the lipid bilayer and binds the receptor's ligand-binding domain, HSP90 dissociates. The testosterone-AR complex then dimerizes, acquires nuclear localization signals, and enters the nucleus within minutes [2]. There, it attaches to androgen response elements (AREs) on DNA and recruits coactivator complexes that drive transcription of target genes: those controlling muscle protein synthesis, erythropoietin production, sebaceous gland activity, and dozens of others [3].

DHT binds the AR with roughly three times higher affinity than testosterone and dissociates more slowly, which is why tissues that express the enzyme 5-alpha reductase (prostate, skin, scalp) show amplified androgenic effects even at moderate serum testosterone concentrations [4]. The clinical implication is direct: a man on TRT whose 5-alpha reductase activity is high may experience scalp hair thinning or prostate volume changes at total testosterone levels that appear unremarkable on a lab report.

AR also signals through non-genomic pathways. Membrane-associated AR can activate second-messenger cascades, including PI3K/Akt and MAPK, within seconds of testosterone binding [5]. These rapid effects partly explain why testosterone influences mood and alertness faster than the hours needed for new gene transcription.

The HPG Axis: Why TRT Shuts Down Natural Production

The hypothalamic-pituitary-gonadal (HPG) axis is a closed feedback loop. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses every 60-90 minutes. Each GnRH pulse triggers the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH travels to Leydig cells in the testes and stimulates testosterone synthesis. Rising testosterone then feeds back to suppress both GnRH pulse frequency and pituitary LH secretion [6].

Exogenous testosterone short-circuits this loop immediately. A single injection of testosterone cypionate 200 mg raises serum testosterone above 1 to 000 ng/dL within 24-48 hours and suppresses LH below 1 mIU/mL in most men within two to four weeks of therapy [7]. With LH absent, intratesticular testosterone (ITT), which is normally 50-100 times higher than serum levels, collapses, and spermatogenesis essentially halts [8]. This is why men pursuing fertility are typically offered alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG), which stimulate LH receptors directly or restore endogenous LH signaling rather than replacing testosterone exogenously.

The Endocrine Society's 2018 clinical practice guideline states: "We suggest against starting testosterone therapy in patients who are currently desiring fertility" [9]. That recommendation flows directly from the HPG suppression mechanism described above.

Recovery of the axis after stopping TRT is variable. A 2021 review in the Journal of Clinical Endocrinology and Metabolism found that LH and FSH return toward baseline in most men within three to six months of cessation, though recovery may take longer after years of use [10]. Testicular volume, which shrinks because of reduced intratesticular testosterone and paracrine signaling, often but not always recovers in parallel.

Free Testosterone, Total Testosterone, and the Role of SHBG

Total testosterone is the sum of every testosterone molecule in plasma, regardless of whether it is bound to a protein or not. The number on a standard lab report captures three fractions simultaneously: testosterone tightly bound to sex hormone-binding globulin (SHBG), testosterone loosely bound to albumin, and the small free fraction that is unattached to any protein.

Only free testosterone can diffuse passively across cell membranes down a concentration gradient. It represents approximately 2-3% of total testosterone in men [11]. Albumin-bound testosterone, which accounts for roughly 38-54% of the total, is held loosely enough that it can dissociate in the capillary bed and become available to tissues, which is why clinicians often measure bioavailable testosterone, the sum of free plus albumin-bound fractions [12].

SHBG-bound testosterone, which constitutes 44-65% of circulating total testosterone, cannot reach the androgen receptor under normal conditions. SHBG binds testosterone with an association constant roughly 1,000-fold higher than albumin, making that fraction effectively sequestered [13].

SHBG concentration itself is regulated by multiple variables: it rises with aging, hyperthyroidism, estrogen exposure, liver disease, and certain anticonvulsants, and it falls with obesity, insulin resistance, hypothyroidism, and glucocorticoid excess [14]. A man with total testosterone of 450 ng/dL and an SHBG of 70 nmol/L may have a free testosterone below 50 pg/mL, well into the symptomatic range despite an apparently adequate total level. A man with total testosterone of 350 ng/dL and SHBG of 18 nmol/L may have free testosterone above 100 pg/mL with no symptoms at all.

The American Urological Association's 2018 guideline defines hypogonadism partly as total testosterone below 300 ng/dL on two morning measurements, but notes explicitly that free or bioavailable testosterone should be assessed when SHBG is abnormal [15]. Calculating free testosterone from measured total testosterone and SHBG using the Vermeulen equation is acceptable when direct immunoassay or equilibrium dialysis is unavailable, though equilibrium dialysis remains the gold standard [16].

How TRT Formulations Affect Receptor Occupancy Over Time

Receptor occupancy follows serum free-testosterone kinetics. A formulation that produces stable, physiologic free testosterone concentrations throughout the day will drive more consistent AR signaling than one that swings from supraphysiologic peaks to subtherapeutic troughs.

Testosterone cypionate and enanthate, both esterified injectables, produce peak serum testosterone within 24-72 hours of injection and decline over seven to ten days. Weekly injections at 100-200 mg typically yield trough total testosterone values between 300-700 ng/dL [17]. Twice-weekly dosing at half the dose flattens the curve considerably, reducing the amplitude of the peak-to-trough swing. That matters clinically because supraphysiologic peaks accelerate aromatization, raising estradiol, which can cause water retention and gynecomastia, while troughs may fall below the threshold for adequate AR occupancy in muscle and bone.

Transdermal testosterone gels (1.62% or 2%) applied daily produce steadier serum concentrations, typically within the 300-800 ng/dL range when dosed at 40.5-81 mg per day [18]. Daily application mimics the diurnal pattern more closely than weekly injections, though transfer to partners or children remains a safety concern requiring handwashing and covered application sites.

Testosterone undecanoate (Aveed) given as 750 mg intramuscular injections at weeks 0, 4, and then every 10 weeks produces a broad pharmacokinetic plateau, keeping total testosterone roughly within 300-900 ng/dL across the dosing interval in most patients [19]. The FDA requires a 30-minute post-injection observation period because of a small risk of pulmonary oil microembolism.

Subcutaneous testosterone pellets (Testopel) inserted every three to six months release testosterone over weeks, but individual pharmacokinetics vary enough that some men experience declining levels before the scheduled reinsertion window [20].

All formulations suppress the HPG axis. The mechanism is identical regardless of the delivery route; the only variable is the serum testosterone concentration profile that drives that suppression.

Estradiol Conversion, Aromatase, and Feedback at the AR Level

Testosterone does not act exclusively through the AR. A meaningful fraction, roughly 0.3% in men, is converted by the aromatase enzyme (CYP19A1) primarily in adipose tissue, liver, and brain to estradiol [21]. Estradiol then binds estrogen receptors alpha and beta, signaling pathways entirely distinct from AR.

Estradiol is not simply a side effect to be suppressed. It is required for libido, bone mineral density maintenance, and cardiovascular health in men. A landmark study by Finkelstein et al. in the New England Journal of Medicine (N=198) demonstrated that sexual desire and erectile function declined when estradiol was suppressed with an aromatase inhibitor, independent of testosterone level [22]. Bone resorption markers rose sharply under estradiol suppression even when testosterone was maintained in the normal range, confirming that AR signaling alone does not fully account for testosterone's skeletal effects.

Men with higher adiposity aromatize more testosterone to estradiol, which both reduces free testosterone (because rising estradiol elevates SHBG) and increases feedback suppression at the pituitary. This creates a cycle where obesity lowers bioavailable testosterone, which promotes further fat accrual, which drives more aromatization. TRT in that context may require attention to body composition alongside hormonal optimization.

Anastrozole (1 mg oral, twice weekly in some TRT protocols) and exemestane are sometimes added to TRT regimens to prevent estradiol-related side effects, but routine use is not supported by guidelines. The Endocrine Society 2018 guideline explicitly states: "We recommend against the routine use of aromatase inhibitors in men receiving testosterone therapy" [9], reserving them for symptomatic hyperestrogenemia with objective estradiol elevation above 40-60 pg/mL.

Androgen Receptor Polymorphisms and Individual Response Variability

Not all androgen receptors are equally sensitive. The AR gene contains a polymorphic CAG trinucleotide repeat in exon 1. Shorter CAG repeats (17-22 repeats) are associated with higher AR transcriptional activity; longer repeats (above 26) reduce receptor sensitivity [23]. Two men with identical free testosterone concentrations may experience dramatically different symptom burdens and treatment responses because of this genetic variation.

A 2010 study in the Journal of Clinical Endocrinology and Metabolism (N=1,954 from the European Male Ageing Study) found that men with longer CAG repeats reported more sexual symptoms at any given testosterone level, consistent with reduced AR sensitivity requiring higher ligand concentrations to achieve equivalent receptor activation [24]. This polymorphism partly explains why some men remain symptomatic at total testosterone of 450 ng/dL while others feel entirely well at 280 ng/dL.

CAG repeat length is not yet routinely tested in clinical TRT practice. However, it offers a mechanistic framework for understanding why symptom-based assessment matters alongside absolute testosterone numbers, and why the AUA guideline supports treating symptomatic men with confirmed biochemical hypogonadism rather than relying on a single numeric threshold alone [15].

Measuring the Right Fractions: A Practical Lab Guide

Total testosterone should be drawn fasting in the morning (7:00-10:00 a.m.) when endogenous LH pulses have driven overnight production to its diurnal peak. Two separate measurements on different days are required to confirm hypogonadism per guideline standards [9].

Free testosterone by equilibrium dialysis is the most accurate method. Calculated free testosterone using the Vermeulen formula requires accurate SHBG and albumin inputs and performs reasonably well when both are measured on the same sample [16]. Direct free testosterone immunoassay, offered by many commercial labs, is less accurate and consistently underestimates true free testosterone at low concentrations; some guidelines explicitly recommend against using it for clinical decisions [25].

Bioavailable testosterone (free plus albumin-bound) can be measured directly by ammonium sulfate precipitation or calculated if albumin is measured. Reference values for bioavailable testosterone in adult men range from approximately 83-257 ng/dL by most lab standards, though reference intervals vary by assay and laboratory [12].

SHBG should be checked at baseline and repeated after six months on TRT, since exogenous testosterone modestly suppresses SHBG over time. Oral testosterone undecanoate (Jatenzo, Tlando) has a stronger SHBG-lowering effect than injectable forms because of first-pass hepatic exposure [26].

LH and FSH should be measured before starting TRT to distinguish primary hypogonadism (elevated LH/FSH indicating testicular failure) from secondary hypogonadism (low or inappropriately normal LH/FSH indicating a pituitary or hypothalamic cause). That distinction changes workup: a man with secondary hypogonadism warrants pituitary MRI to exclude a prolactinoma or other mass lesion [9].

A prolactin level above 35 ng/mL in a hypogonadal man warrants immediate pituitary imaging before any testosterone is prescribed [27].

Receptor Downregulation, Upregulation, and Clinical Saturation

Prolonged supraphysiologic androgen exposure can downregulate AR expression in certain tissues. In vitro data and animal models show that AR mRNA and protein decrease after sustained high-dose androgen stimulation, though the clinical relevance in men on therapeutic (not supraphysiologic) TRT remains debated [28]. This mechanism is more relevant to pharmacologic doses used in anabolic-androgenic steroid abuse than to guideline-directed TRT.

At therapeutic doses, receptor saturation appears to occur at total testosterone concentrations near 500-600 ng/dL for skeletal muscle in most studies, meaning that pushing total testosterone above 800-1 to 000 ng/dL through aggressive dosing may not produce proportionally greater anabolic benefit while increasing the risk of polycythemia, sleep apnea exacerbation, and cardiovascular strain [29].

The TRAVERSE trial (N=5,246, mean age 65.6 years), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism and elevated cardiovascular risk did not significantly increase the rate of major adverse cardiovascular events compared to placebo over a median 33 months, with a hazard ratio of 0.96 (95% CI 0.78-1.17, P<0.001 for non-inferiority) [30]. Atrial fibrillation was more common in the testosterone group (3.5% vs. 2.4%), a finding that warrants consideration when counseling men with pre-existing arrhythmias.

TRT Monitoring: Connecting Mechanism to Lab Targets

Because AR occupancy depends on free testosterone, not total testosterone, and because SHBG modulates that relationship dynamically, monitoring TRT by total testosterone alone misses clinically meaningful variation.

A practical approach follows the mechanism: check total testosterone, free testosterone (calculated or by dialysis), SHBG, estradiol, hematocrit, and PSA at baseline, then at 3 months, 6 months, and annually thereafter [15]. Target total testosterone mid-range, roughly 400-700 ng/dL, rather than pushing toward the upper limit of normal. Free testosterone targets depend on assay method, but a calculated free testosterone above 100 pg/mL by the Vermeulen equation is a reasonable threshold for most symptomatic men.

Hematocrit above 54% requires dose reduction or therapeutic phlebotomy, since erythropoiesis is one of the most AR-sensitive endpoints and polycythemia increases thrombotic risk [9]. PSA should remain stable; a confirmed rise above 1.4 ng/mL from baseline within 12 months or any single measurement above 4.0 ng/mL warrants urology referral before TRT continuation [15].

Men whose free testosterone normalizes but symptoms persist should prompt re-evaluation of the diagnosis, AR CAG repeat polymorphism as a contributor, concurrent thyroid dysfunction, sleep apnea, or depression, rather than automatic dose escalation.